Ganesh Sambasivam files substantial acquisition disclosure in Anthem Biosciences under SEBI Takeover Code

M&A / JV 23 Jun 2026 · Announced· ✓ Verified

Ganesh Sambasivam has filed a substantial acquisition disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulations 31(4) and 31(5), with the National Stock Exchange. This disclosure is mandatory when an acquirer, either alone or in concert with associates, has purchased shares and/or voting rights such that the aggregate holding crosses the 25% threshold (or such other specified slab) in a listed company. The filing marks the public announcement of the acquisition and triggers a 60-day open-offer period (if applicable) during which the acquirer must make a public offer to acquire shares from public shareholders at a price not less than the highest…

Why it mattersThe Regulation 31(4)–(5) disclosure regime requires acquirers crossing the 25% threshold to make public disclosure within two trading days; this filing initiates the takeover clock and potential open-offer obligation, requiring counsel to verify trigger thresholds, exemptions (e.g., preferential issue, inter-se transfer), and the target's board response under Schedule III.
Counsel—
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals